기관지천식의 최신 약물 치료 지침
Updated drug therapy guideline of asthma
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Asthma is a serious health problem throughout the world with high prevalence and increased socioeconomic burden. So in order to have a better understanding and medication for this illness, many scientific advances have been made. To specify, Global Initiative for Asthma (GINA) and National Asthma Education and Prevention Program (NAEPP) have played a leading role in disseminating information about the care for patients based on a process of continuous review of published scientific investigations. For these outstanding accomplishments, GINA and NAEPP guidelines are now being widely adopted, translated and reproduced, forming the basis for many national guidelines throughout the world. These guidelines recommend a change in approach to asthma management with asthma control, rather than asthma severity, being the focus of treatment decisions. Most importantly, these provide stepwise drug therapy of asthma based on the level of control. This session will mainly focus on updated stepwise drug therapy.
Abstract
Asthma is a serious health problem throughout the world with high prevalence and increased socioeconomic burden. So in order to have a better understanding and medication for this illness, many scientific advances have been made. To specify, Global Initiative for Asthma (GINA) and National Asthma Education and Prevention Program (NAEPP) have played a leading role in disseminating information about the care for patients based on a process of continuous review of published scientific investigations. For these outstanding accomplishments, GINA and NAEPP guidelines are now being widely adopted, translated and reproduced, forming the basis for many national guidelines throughout the world. These guidelines recommend a change in approach to asthma management with asthma control, rather than asthma severity, being the focus of treatment decisions. Most importantly, these provide stepwise drug therapy of asthma based on the level of control. This session will mainly focus on updated stepwise drug therapy.
참고문헌 (35)
- "2007 국민건강통계 국민건강영양조사 제4기 1차년도(2007). 보건복지가족부, 질병관리본부", ~ (2008)
- "Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007", J Allergy Clin Immunol, 120, pp.S94~S138 (2007)
- Nathan RA, "Development of the asthma control test: a survey for assessing asthma control", J Allergy Clin Immunol, 113, pp.59~65 (2004)
- Juniper EF, "Validation of a standardized version of the Asthma Quality of Life Questionnaire", Chest, 115, pp.1265~1270 (1999)
- Vollmer WM, "Association of asthma control with health care utilization and quality of life", Am J Respir Crit Care Med, 160, pp.1647~1652 (1999)
- Boulet LP, "How should we quantify asthma control? A proposal", Chest, 122, pp.2217~2223 (2002)
- Pauwels RA, "START Investigators Group. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial", Lancet, 361, pp.1071~1076 (2003)
- O’Byrne PM, "Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial", Am J Respir Crit Care Med, 164, pp.1392~1397
- Adams NP, "Inhaled beclomethasone versus placebo for chronic asthma", Cochrane Database Syst Rev, pp.CD002738~ (2005)
- Barnes NC, "Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials", Thorax, 55, pp.478~483 (2000)
- Drazen JM, "Treatment of asthma with drugs modifying the leukotriene pathway", N Engl J Med, 340, pp.197~206 (1999)
- Bleecker ER, "Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma", J Allergy Clin Immunol, 105, pp.1123~1129 (2000)
- Wilson AM, "A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma", Clin Exp Allergy, 31, pp.616~624 (2001)
- Francis RS, "Disodium cromoglycate compared with beclomethasone dipropionate in juvenile asthma", Clin Allergy, 14, pp.537~540 (1984)
- Lazarus SC, "Asthma Clinical Research Network for the National Heart, Lung, and Blood Institute. Long-acting b-2-agonist monotherapy versus continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial", JAMA, 285, pp.2583~2593 (2001)
- Lemanske RF Jr, "Asthma Clinical Research Network for the National Heart, Lung, and Blood Institute. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial", JAMA, 285, pp.2594~2603 (2001)
- Shrewsbury S, "Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)", BMJ, 320, pp.1368~1373 (2000)
- Bateman ED, "GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study", Am J Respir Crit Care Med, 170, pp.836~844 (2004)
- Szefler SJ, "Asthma Clinical Research Network of the National Heart Lung, and Blood Institute. Significant variability in response to inhaled corticosteroids for persistent asthma", J Allergy Clin Immunol, 109, pp.410~418 (2002)
- Fish JE, "Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy", Chest, 120, pp.423~430 (2001)
- Pauwels RA, "Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group", N Engl J Med, 337, pp.1405~1411 (1997)
- Bateman ED, "Global strategy for asthma management and prevention: GINA executive summary", Eur Respir J, 31, pp.143~178 (2008)
- Price DB, "Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma", Thorax, 58, pp.211~216 (2003)
- Mash B, "Inhaled versus oral steroids for adults with chronic asthma", Cochrane Database Syst Rev, pp.CD002160~ (2000)
- Ayres JG, "Brittle asthma", Paediatr Respir Rev, 5, pp.40~44 (2004)
- Milgrom H, "Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group", N Engl J Med, 341, pp.1966~1973 (1999)
- Djukanovic R, "Effects of treatment with antiimmunoglobulin E antibody omalizumab on airway inflammation in allergic asthma", Am J Respir Crit Care Med, 170, pp.583~593 (2004)
- Holgate ST, "Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma", Clin Exp Allergy, 34, pp.632~638 (2004)
- Reddel HK, "Optimal asthma control, starting with high doses of inhaled budesonide", Eur Respir J, 16, pp.226~235 (2000)
- Powell H, "Initial starting dose of inhaled corticosteroids in adults with asthma: a systematic review", Thorax, 59, pp.1041~1045 (2004)
- Boulet LP, "Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma", Respir Med, 100, pp.785~794 (2006)
- Bateman ED, "Budesonide", formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol, 2006, pp.7, 13~
- Reddel HK, "Pharmacological strategies for selfmanagement of asthma exacerbations", Eur Respir J, 28, pp.182~199 (2006)
- Rabe KF, "Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study", Lancet, 368, pp.744~753 (2006)